摘要
目的探讨尿激酶和瑞替普酶在治疗肺动脉栓塞中的效果和安全性。方法选取2009年4月至2012年4月在我院治疗的51例肺动脉栓塞患者作为研究对象,随机分为2组。研究组32例,给予瑞替普酶;对照组19例,采用尿激酶溶栓治疗。观察溶栓前后患者肺动脉压(PAP)、动脉氧分压(PaO2)、血压(SBP)及出血并发症情况。结果治疗后,研究组总有效率为90.6%,对照组为73.7%,两组比较差异有统计学意义(P<0.05);两组患者PAP降低,PaO2、SBP上升,治疗前后比较差异有统计学意义(P<0.05)。两组患者主要不良反应包括牙龈出血、咯血、消化道出血、穿刺点出血及寒战等,且研究组牙龈出血、咯血和穿刺点出血等不良反应发生率明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论瑞替普酶治疗肺动脉栓塞效果明显优于尿激酶,且出血发生率较低,值得临床推广。
Objective To explore the efficacy and safety of urokinase and reteplase in the treatment of pulmo- nary embolism. Methods 51 patients with pulmonary artery embolism from April 2009 to April 2012 in our hospital were selected as research objects, they were randomly divided into 2 groups, study group（ n = 32）was treated with reteplase, control group（ n = 19 ） was given urokinase thrombolytic. The PAP, PaO2 , SBP and bleeding complications of patients were recorded before and after thrombolytic therapy. Results After treatment, the total effective rate in study group was higher than that of control group（90.6% vs. 73.7% ,P 〈 0.05 ） ;the PAP of the two groups decreased sig- nificantly （ P 〈 0.05 ）, PaO2 and SBP increased significantly （ P 〈 0.05 ） ; Gingival bleeding, hemoptysis, gastrointestinal bleeding, puncturing site bleeding and shilvering were the main adverse reactions. The incidence of adverse reaction in study group was lower than that of control group （ P 〈 0.05 ）. Conclusion The effect of reteplase on pulmonary embolism is obviously better than that of urokinase, with lower bleeding rate,it is worth the clinical promotion.
出处
《实用药物与临床》
CAS
2013年第12期1214-1216,共3页
Practical Pharmacy and Clinical Remedies
